CliffBio

Karyopharm Therapeutics

Patent cliffs & loss of exclusivity

Karyopharm Therapeutics is a commercial-stage pharmaceutical company developing and commercializing cancer therapies targeting nuclear export. Its marketed medicine is XPOVIO (selinexor).

Company

AngelList URLhttps://angel.co/karyopharm-therapeutics
CAGE Code7FSV2
Legal NameKaryopharm Therapeutics Inc.
Company Operating StatusActive
Contact Page URLhttps://www.karyopharm.com/contact-us/
Crunchbase URLhttps://www.crunchbase.com/organization/karyopharm-therapeutics
Email format{first}.{last}
Facebook URLhttp://www.facebook.com/KaryopharmTherapeutics

6 upcoming patent cliffs

DrugIngredientTypeCliff
  1. XPOVIOSELINEXORSmall mol.Aug 2035
  2. XPOVIOSELINEXORSmall mol.Aug 2035
  3. XPOVIOSELINEXORSmall mol.Aug 2035
  4. XPOVIOSELINEXORSmall mol.Aug 2035
  5. XPOVIOSELINEXORSmall mol.Aug 2035
  6. XPOVIOSELINEXORSmall mol.Aug 2035

Loss-of-exclusivity dates are derived from the FDA Orange & Purple Books; company detail is from the CliffBio graph. Estimates are projections, not legal advice.